Cargando…

Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma

The therapeutic landscape for advanced clear cell renal cell carcinoma (ccRCC) is rapidly evolving with improved knowledge of the biology of disease leading to the incorporation of a variety of antiangiogenic agents and immunotherapies. In this review, we discuss historical, current, and emerging fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serzan, Michael T., Atkins, Michael B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923624/ https://www.ncbi.nlm.nih.gov/pubmed/35295921 http://dx.doi.org/10.20517/2394-4722.2021.76

Ejemplares similares

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
por: Aeppli, S., et al.
Publicado: (2021)

Metastatic clear cell renal carcinoma – an unusual response to Temsirolimus in second line therapy
por: Stanculeanu, DL, et al.
Publicado: (2016)

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma
por: Astore, Serena, et al.
Publicado: (2023)

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
por: Xu, Kevin Y, et al.
Publicado: (2015)

Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2021)

Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy
por: Park, Yong Hyun, et al.
Publicado: (2014)

Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K., et al.
Publicado: (2022)

Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma
por: Toth, Alexander T., et al.
Publicado: (2020)

Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies
por: Sankin, Alexander, et al.
Publicado: (2015)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022)

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
por: Bonadioa, Renata Colombo, et al.
Publicado: (2019)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
por: Nerich, Virginie, et al.
Publicado: (2014)

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
por: van der Mijn, Johannes C., et al.
Publicado: (2022)

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
por: McDermott, David F., et al.
Publicado: (2021)

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
por: McDermott, David F., et al.
Publicado: (2021)

Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
por: Serzan, Michael T, et al.
Publicado: (2020)

Emerging Targets in Clear Cell Renal Cell Carcinoma
por: Chen, Yu-Wei, et al.
Publicado: (2022)

Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma
por: Popovic, Maja, et al.
Publicado: (2022)

VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas
por: Zhou, Jiale, et al.
Publicado: (2022)

Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
por: Gupta, Dharna, et al.
Publicado: (2023)

Editorial: The ever-changing scenario of first line treatment of metastatic renal cell carcinoma
por: Vitale, Maria Giuseppa, et al.
Publicado: (2023)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
por: Osterman, Chelsea K., et al.
Publicado: (2020)

Genetic mutations associated with metastatic clear cell renal cell carcinoma
por: Li, Zhongjun, et al.
Publicado: (2016)

Combination drug regimens for metastatic clear cell renal cell carcinoma
por: Khetani, Viraj V, et al.
Publicado: (2020)

Metastatic Clear Cell Renal Cell Carcinoma Presenting as Acute Appendicitis
por: Ushakova, Oxana, et al.
Publicado: (2023)

Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
por: Zeuschner, Philip, et al.
Publicado: (2021)

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients
por: Tan, Xiaojie, et al.
Publicado: (2013)

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
por: Haaland, Benjamin, et al.
Publicado: (2014)

Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions
por: Tung, Iris, et al.
Publicado: (2021)

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
por: Kraljević, Marija, et al.
Publicado: (2023)

Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
por: Aeppli, Stefanie, et al.
Publicado: (2020)

Management of metastatic renal cell carcinoma in patients with poor prognosis
por: Bullock, Andrea, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5bvs731oqtttlf9bk7t4l2j9v0